TY - JOUR T1 - Impact of alpha-1 antitrypsin level on longitudinal lung function change: The Nagahama Study JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2019.PA2025 VL - 54 IS - suppl 63 SP - PA2025 AU - Satoshi Hamada AU - Kimihiko Murase AU - Yasuharu Tabara AU - Takuma Minami AU - Naomi Takahashi AU - Yoshinari Nakatsuka AU - Hirofumi Takeyama AU - Toyohiro Hirai AU - Fumihiko Matsuda AU - Tomohiro Handa AU - Kazuo Chin Y1 - 2019/09/28 UR - http://erj.ersjournals.com/content/54/suppl_63/PA2025.abstract N2 - Background: Systemic inflammation can be associated with an accelerated decrease in pulmonary function in the general population. Alpha-1 antitrypsin (AAT) is a major protease inhibitor and its deficiency is one of the most common risk factors for developing early onset emphysema and chronic obstructive pulmonary disease. Recently, AAT has been recognized as a systemic inflammation marker. However, the association between AAT levels and longitudinal forced expiratory volume in one second (FEV1) changes has been unknown in the general population.Aims and Objectives: To examine the association between baseline AAT levels and longitudinal FEV1 changes in a general population-based large-scale cohort study.Methods: This study included 9,053 Japanese participants (male 2,962; female 6,091), in whom 7,525 (male 2,397; female 5,128) were included in the longitudinal analysis. The change in FEV1 was calculated by dividing the difference between the baseline and follow-up by follow-up periods (years). The change in FEV1 was categorized into two groups: rapid decline (change in FEV1 <–90mL/year) and non-rapid decline (change in FEV1 ≥–90mL/year).Results: Follow-up period was 1815 ± 135 days. FEV1 decreased by 34.2 ± 0.6 ml/year during the follow-up period. There were 862 (11.5%) participants with the rapid decline in FEV1. The elevation of baseline AAT levels was independently associated with the rapid decline in FEV1 (odds ratio = 1.09; 95% confidence interval = 1.04–1.14; p = 0.0004), although baseline AAT levels were not associated with baseline FEV1.Conclusions: The present findings imply that baseline AAT levels might become a new predicting factor for longitudinal FEV1 decline.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA2025.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -